COMMUNIQUÉS West-GlobeNewswire

Sequana Medical announces data on alfapump® safety and quality of life to be presented at EASL Congress 2024
06/06/2024
Sequana Medical announces data on alfapump® safety and quality of life to be presented at EASL Congress 2024 “alfapump implantation significantly improved quality of life and showed similar safety outcomes compared to a [...]
Annexon Announces Pricing of $125 Million Underwritten Public Offering
06/06/2024
BRISBANE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical [...]
Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering
06/06/2024
SAN FRANCISCO, June 05, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and [...]
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
05/06/2024
HOUSTON, June 05, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology [...]
Monthly information on share capital and company voting rights
05/06/2024
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, June 05, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the [...]
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
05/06/2024
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 05 juin 2024 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 Date Nombre total d’actions composant le [...]
DBV Technologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
05/06/2024
Châtillon, France, June 5, 2024 DBV Technologies to Participate in the Goldman Sachs 45 th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a [...]
DBV Technologies participera à la 45e conférence annuelle Goldman Sachs Global Healthcare
05/06/2024
Châtillon, France, le 5 juin (22 :30 CEST) 2024 DBV Technologies participera à la 45e conférence annuelle Goldman Sachs Global Healthcare DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT— [...]
AVITA Medical Achieves Milestone with First Case Using RECELL GO
05/06/2024
Joseph M. Still Burn Center at Doctors Hospital of Augusta first to treat a patient using AVITA Medical’s FDA-Approved RECELL GO System for thermal burn wounds and full-thickness skin defects VALENCIA, Calif., June 05, [...]
Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference
05/06/2024
WALTHAM, Mass. and DUBLIN, June 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to [...]
SI-BONE To Present at Truist Securities 2024 MedTech Conference on June 18, 2024
05/06/2024
SANTA CLARA, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company [...]
Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
05/06/2024
REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced [...]
Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608
05/06/2024
Initial triplet combination of RLY-2608 + atirmociclib + fulvestrant to be evaluated in patients with PI3Kα-mutated HR+/HER2- metastatic breast cancer; initiation planned by end of 2024 CAMBRIDGE, Mass., June 05, 2024 ( [...]
QIAGEN launches digital PCR Assay Design Tool for QIAcuity, expands customization capabilities of its research platform GeneGlobe
05/06/2024
New QIAcuity digital PCR Custom Assay Design Tool for copy number variation analysis supports researchers’ customization needs, complementing QIAGEN’s existing pre-designed assays // GeneGlobe Design and Analysis Hub [...]
ImmuCell Provides Update on Regulatory Status of Product Development Initiative for Re-Tain®
05/06/2024
PORTLAND, Maine , June 05, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and [...]
RxSight, Inc. To Participate in the Truist Securities Medtech Conference
05/06/2024
ALISO VIEJO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced [...]
Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
05/06/2024
VANCOUVER, British Columbia, June 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the Goldman [...]
Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers
05/06/2024
VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice Additive effects were observed for VTX3232 in combination with the GLP [...]
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/06/2024
WESTLAKE VILLAGE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, [...]

Pages